Edition:
United Kingdom

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

1.69USD
5:00pm GMT
Change (% chg)

$0.03 (+1.81%)
Prev Close
$1.66
Open
$1.66
Day's High
$1.71
Day's Low
$1.66
Volume
8,781
Avg. Vol
18,286
52-wk High
$35.00
52-wk Low
$1.65

Latest Key Developments (Source: Significant Developments)

Altimmune reports Q3 loss per share $2.05
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Altimmune Inc :Altimmune announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $2.05.Q3 preliminary loss per share $0.34 excluding items.Altimmune Inc qtrly revenue and grants and contracts were $4.6 million versus $0.9 million​.Altimmune Inc - ‍at september 30, 2017, company had cash and cash equivalents of approximately $17.1 million​.Altimmune Inc - ‍initiated a phase 2 clinical trial with nasovax vaccine with initial data expected in q1 2018​.  Full Article

PharmAthene reports Q3 earnings per share $1.67
Friday, 4 Nov 2016 

PharmAthene Inc - : If SIGA pays Co cash in full on judgment,barring unexpected material events, intends to distribute at least 90% of after tax proceeds of payment to shareholders . PharmAthene reports third quarter 2016 financial and operational results . Q3 earnings per share $1.67 .Q3 revenue $1.0 million versus $1.2 million.  Full Article

Pharmathene withdraws protest against HHS over anthrax vaccine bidding process
Thursday, 25 Aug 2016 

Pharmathene Inc : Pharmathene withdraws protest against HHS over anthrax vaccine bidding process .After discussions with biomedical advanced research and development authority, has withdrawn protest filed on August 5, 2016.  Full Article

Pharmathene says "protests" Dept of Health and Human Services anthrax vaccine solicitation
Friday, 5 Aug 2016 

Pharmathene Inc: "Formal protest" against Department of Health and Human Services, challenging solicitation for "next-generation anthrax vaccine provider" . As per complaint, government's "request for proposals" written in a way that assures source award to Emergent Biosolutions, which makes anthrax vaccine ."Protest requests GAO suspend award under solicitation while it reviews Pharmathene's complaint".  Full Article

Pharmathene Q2 earnings per share $0.12
Thursday, 4 Aug 2016 

Pharmathene Inc : Pharmathene reports second quarter 2016 financial and operational results . Q2 revenue $2.1 million versus $1.1 million .Q2 earnings per share $0.12.  Full Article

Pharmathene gets $20 mln payment from Siga to extend payment deadline
Friday, 8 Jul 2016 

Pharmathene Inc : Received payment from Siga Technologies to extend until October 19, 2016, date by which Siga must satisfy pharmathene judgment . Payment is creditable against final satisfaction of judgment in favor of pharmathene of about $205 million plus interest and is not refundable .Pharmathene receives $20 million payment from Siga to extend payment deadline.  Full Article

Pharmathene reports Q1 loss per share $0.02
Monday, 9 May 2016 

Pharmathene Inc : Pharmathene reports first quarter 2016 financial and operational results . Q1 loss per share $0.02 .Q1 revenue $1.0 million versus $7.1 million.  Full Article

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update